Steffens Sabine, Mach Francois
Division of Cardiology, Department of Medicine, University Hospital, Foundation for Medical Research, 64 Avenue Roseraie, 1211 Geneva, Switzerland.
Semin Vasc Med. 2004 Nov;4(4):417-22. doi: 10.1055/s-2004-869599.
Increasing clinical and experimental evidence indicates that some beneficial effects of statins, known as efficient therapeutic agents in cardiovascular disease treatment, may result from their ability to modulate vascular and endothelial cell gene expression by mechanisms independent of cholesterol reduction. It has been shown that statins exhibit direct anti-inflammatory properties via inhibition of proinflammatory cytokine and chemokine secretion, as well as through adhesion molecule expression on leukocytes. Another important mechanism by which statins may modulate the immune response is inhibition of interferon gamma-induced expression of class II major histocompatibility complexes. Class II major histocompatibility complex expression is central to immune regulation in T cell-mediated autoimmune diseases, indicating a potential beneficial role of statins in these pathologies. Indeed, promising new preclinical data indicate that statins might be useful in the treatment of multiple sclerosis and rheumatoid arthritis.
越来越多的临床和实验证据表明,他汀类药物作为心血管疾病治疗中的有效治疗剂,其一些有益作用可能源于它们通过独立于降低胆固醇的机制调节血管和内皮细胞基因表达的能力。已经表明,他汀类药物通过抑制促炎细胞因子和趋化因子的分泌以及通过白细胞上粘附分子的表达表现出直接的抗炎特性。他汀类药物调节免疫反应的另一个重要机制是抑制干扰素γ诱导的II类主要组织相容性复合体的表达。II类主要组织相容性复合体的表达是T细胞介导的自身免疫性疾病免疫调节的核心,这表明他汀类药物在这些病症中具有潜在的有益作用。事实上,有前景的新临床前数据表明,他汀类药物可能对治疗多发性硬化症和类风湿性关节炎有用。